22 drug(s) with this reaction
28,251 total reports
Product Use In Unapproved Indication has been reported as an adverse reaction across 22 drug(s) manufactured by Haleon Us Holdings Llc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 28,251 adverse event reports mention product use in unapproved indication in connection with Haleon Us Holdings Llc products.
This page provides a breakdown of which Haleon Us Holdings Llc drugs are most commonly associated with product use in unapproved indication, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Haleon Us Holdings Llc drugs have product use in unapproved indication listed in their FDA adverse event reports, sorted by report count:
In addition to product use in unapproved indication, the following adverse reactions have been reported across Haleon Us Holdings Llc's drug portfolio:
22 drug(s) manufactured by Haleon Us Holdings Llc have product use in unapproved indication listed in their FDA adverse event reports: DICLOFENAC SODIUM, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, FLUTICASONE PROPIONATE, ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE, CALCIUM CARBONATE, and others.
There are a combined 28,251 reports of product use in unapproved indication across 22 Haleon Us Holdings Llc drug(s) in the FDA adverse event database.